Alexion to Highlight Robust Rare Disease Pipeline at Investor Day
November 19 2015 - 10:00AM
Business Wire
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) today announced that
the Company will host an Investor Day on Thursday, December 10,
2015 from 12:00 p.m. to 5:00 p.m. Eastern Standard Time in New York
City.
Alexion’s leadership team will highlight the continued
advancement of the Company’s highly innovative early and late-stage
pipeline which is focused on serving patients with devastating and
rare diseases. The company will also provide updates on key aspects
of its long-term growth strategy for its complement and metabolic
franchises.
Webcast/Conference Call Information
The presentation will be broadcast via a live webcast which can
be accessed on the Investor page of Alexion’s website at:
http://ir.alexionpharm.com. A replay of the webcast will be
archived on the website following the presentation. To participate
in this conference call, dial 866-546-3377 (USA) or 719-234-7872
(International), passcode 737 644 3057 shortly before 12:00 p.m.
ET.
About Alexion
Alexion is a global biopharmaceutical company focused on
developing and delivering life-transforming therapies for patients
with devastating and rare disorders. Alexion developed and
commercializes Soliris® (eculizumab), the first and only
approved complement inhibitor to treat patients with paroxysmal
nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic
syndrome (aHUS), two life-threatening ultra-rare disorders. As the
global leader in complement inhibition, Alexion is strengthening
and broadening its portfolio of complement inhibitors, including
evaluating potential indications for eculizumab in additional
severe and ultra-rare disorders. Alexion’s metabolic franchise
includes two highly innovative enzyme replacement therapies for
patients with life-threatening and ultra-rare disorders, Strensiq™
(asfotase alfa) to treat patients with hypophosphatasia (HPP) and
Kanuma™ (sebelipase alfa) to treat patients with lysosomal acid
lipase deficiency (LAL-D). In addition, Alexion is advancing the
most robust rare disease pipeline in the biotech industry, with
highly innovative product candidates in multiple therapeutic areas.
This press release and further information about Alexion can be
found at: www.alexion.com.
[ALXN-G]
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151119005756/en/
Alexion Pharmaceuticals Inc.Media:Stephanie Fagan,
203-271-8223Senior Vice President, Corporate CommunicationsorKim
Diamond, 203-439-9600Executive Director, Corporate
CommunicationsorInvestors:Elena Ridloff, CFA, 203-699-7722Executive
Director, Investor Relations
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Mar 2023 to Mar 2024